Hand–foot syndrome in sorafenib and lenvatinib treatment for advanced thyroid cancer

作者
Elisa Minaldi,Virginia Cappagli,Loredana Lorusso,Laura Valerio,Carlotta Giani,Matilde Viglione,Laura Agate,Eleonora Molinaro,Antonio Matrone,Rossella Elisei
出处
期刊:European thyroid journal [Karger Publishers]
卷期号:13 (4) 被引量:4
标识
DOI:10.1530/etj-24-0009
摘要

Objective: The aim of this study was to assess the clinical impact of hand-foot syndrome (HFS) during treatment with two multikinase inhibitors, sorafenib and lenvatinib, in a large group of patients with advanced thyroid cancer. Moreover, we looked for possible associations between HFS occurrence and clinical and pathological features. Methods: We retrospectively evaluated 239 patients with advanced thyroid cancer: 165 treated with lenvatinib and 74 with sorafenib. Statistical analyses were performed to verify which features could be correlated with HFS development. Results: HFS was observed in 35/74 (47.4%) and in 43/165 (26.7%) patients treated with sorafenib or lenvatinib, respectively. The median latency from the drug beginning and HFS appearance was 27 days for sorafenib and 2.9 months for lenvatinib. G3/G4 toxicity was observed in 16/35 (45.7%) patients treated with sorafenib and only in 3/43 (7%) treated with lenvatinib. Drug dose reduction due to HFS was required in 19/74 (25.7%) and 3/165 (1.8%) patients treated with sorafenib and lenvatinib, respectively. HFS occurrence was significantly associated with a longer duration of therapy in both groups. Conclusion: HFS was a frequent adverse event during both lenvatinib and sorafenib therapy, with a higher frequency and toxicity grade during sorafenib treatment. HFS was the most frequent reason for drug reduction or discontinuation in patient treated with sorafenib. Early diagnosis of HFS is important to allow early intervention, possibly in a multidisciplinary setting, and to avoid treatment discontinuation, which is highly relevant to obtain the maximum effectiveness of systemic therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
三哼发布了新的文献求助10
1秒前
1秒前
地道的反差萌完成签到,获得积分10
1秒前
黄鑫发布了新的文献求助10
2秒前
喜悦桥发布了新的文献求助10
2秒前
小马甲的应助被眼睛大友桃采纳,获得10
2秒前
所所的应助被辽沈最美女博采纳,获得10
3秒前
CCCZQ发布了新的文献求助10
3秒前
依然完成签到,获得积分10
3秒前
淡然的含卉的应助被嘿嘿采纳,获得20
3秒前
奋斗觅海发布了新的文献求助10
4秒前
liucheng发布了新的文献求助10
4秒前
小福同学完成签到,获得积分10
4秒前
研友_VZG7GZ的应助被客观的hi采纳,获得20
4秒前
奋斗觅海发布了新的文献求助10
4秒前
田様的应助被俊逸的问兰采纳,获得10
5秒前
奋斗觅海发布了新的文献求助10
5秒前
5秒前
sky发布了新的文献求助10
5秒前
三哼完成签到 ,获得积分10
5秒前
顾矜的应助被Cheung2121采纳,获得10
5秒前
我是老大的应助被ayzzdbr采纳,获得10
5秒前
奋斗觅海发布了新的文献求助10
5秒前
5秒前
曙光发布了新的文献求助30
5秒前
奋斗觅海发布了新的文献求助10
6秒前
keke发布了新的文献求助10
6秒前
CipherSage的应助被zwwwj采纳,获得30
6秒前
田様的应助被MIssing89采纳,获得10
7秒前
7秒前
xixi完成签到,获得积分10
7秒前
无花果的应助被April采纳,获得10
7秒前
从容小蘑菇完成签到,获得积分10
7秒前
谷粱诗云完成签到 ,获得积分10
7秒前
王王发布了新的文献求助10
8秒前
8秒前
薛雨加田完成签到 ,获得积分10
8秒前
bkagyin的应助被很有用采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162816
求助须知:如何正确求助?哪些是违规求助? 9557103
关于积分的说明 21738393
捐赠科研通 7753330
什么是DOI,文献DOI怎么找? 3427963
关于科研通互助平台的介绍 2552742
邀请新用户注册赠送积分活动 2472556